Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Alexion Pharmaceuticals has received priority review status for its supplemental biologics license application (sBLA) for Soliris (eculizumab) from the US Food and Drug Administration (FDA).
Subscribe to our email newsletter
Soliris (eculizumab) is indicated as a treatment for patients with atypical hemolytic uremic syndrome (aHUS).
Alexion plans to launch the drug for the treatment of aHUS in the US in the fourth quarter of 2011.
Moreover, the European Medicines Agency (EMA) is also reviewing a marketing application for Soliris as a treatment for patients with aHUS in the European Union.